학술논문
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Document Type
Article
Author
Livingstone, Elisabeth; Zimmer, Lisa; Hassel, Jessica C; Fluck, Michael; Eigentler, Thomas K; Loquai, Carmen; Haferkamp, Sebastian; Gutzmer, Ralf; Meier, Friedegund; Mohr, Peter; Hauschild, Axel; Schilling, Bastian; Menzer, Christian; Kiecker, Felix; Dippel, Edgar; Roesch, Alexander; Ziemer, Mirjana; Conrad, Beate; Körner, Silvia; Simon, Jan-Christoph; Herbst, Rudolf A; Berking, Carola; Utikal, Jochen; Sell, Sabine; Martens, Uwe M; Terheyden, Patrick; Stadler, Rudolf; Windemuth-Kieselbach, Christine; Schwarz, Leonora; Garbe, Claus; Becker, Jürgen C; Schadendorf, Dirk
Source
In The Lancet 1-7 October 2022 400(10358):1117-1129
Subject
Language
ISSN
0140-6736